Boulding Mark E.'s most recent trade in PTC Therapeutics Inc was a trade of 1,929 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on May 15, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| PTC Therapeutics Inc | Mark E. Boulding | EXEC. VP AND CLO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 May 2025 | 1,929 | 28,595 | - | - | Stock Option (Right to Buy) | |
| PTC Therapeutics Inc | Mark E. Boulding | EXEC. VP AND CLO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 25.69 per share. | 15 May 2025 | 1,929 | 105,830 (0%) | 0% | 25.7 | 49,556 | Common Stock |
| PTC Therapeutics Inc | Mark E. Boulding | EXEC. VP AND CLO | Sale of securities on an exchange or to another person at price $ 46.18 per share. | 15 May 2025 | 1,929 | 103,901 (0%) | 0% | 46.2 | 89,081 | Common Stock |
| PTC Therapeutics Inc | Mark E. Boulding | EXEC. VP AND CLO | Sale of securities on an exchange or to another person at price $ 46.02 per share. | 15 May 2025 | 883 | 103,901 (0%) | 0% | 46.0 | 40,636 | Common Stock |
| PTC Therapeutics Inc | Mark E. Boulding | EXEC. VP AND CLO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 May 2025 | 883 | 27,712 | - | - | Stock Option (Right to Buy) | |
| PTC Therapeutics Inc | Mark E. Boulding | EXEC. VP AND CLO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 25.69 per share. | 15 May 2025 | 883 | 104,784 (0%) | 0% | 25.7 | 22,684 | Common Stock |
| PTC Therapeutics Inc | Mark E. Boulding | EXEC. VP AND CLO | Sale of securities on an exchange or to another person at price $ 53.31 per share. | 12 Mar 2025 | 13,126 | 103,901 (0%) | 0% | 53.3 | 699,747 | Common Stock |
| PTC Therapeutics Inc | Mark E. Boulding | EXEC. VP AND CLO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 33.02 per share. | 12 Mar 2025 | 13,126 | 117,027 (0%) | 0% | 33.0 | 433,421 | Common Stock |
| PTC Therapeutics Inc | Mark E. Boulding | EXEC. VP AND CLO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Mar 2025 | 13,126 | 0 | - | - | Stock Option (Right to Buy) | |
| PTC Therapeutics Inc | Mark E. Boulding | EXEC. VP AND CLO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 33.02 per share. | 12 Mar 2025 | 2,395 | 106,296 (0%) | 0% | 33.0 | 79,083 | Common Stock |
| PTC Therapeutics Inc | Mark E. Boulding | EXEC. VP AND CLO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Mar 2025 | 2,395 | 0 | - | - | Stock Option (Right to Buy) | |
| PTC Therapeutics Inc | Mark E. Boulding | EXEC. VP AND CLO | Sale of securities on an exchange or to another person at price $ 53.23 per share. | 12 Mar 2025 | 2,395 | 103,901 (0%) | 0% | 53.2 | 127,486 | Common Stock |
| PTC Therapeutics Inc | Mark E. Boulding | EXEC. VP AND CLO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2025 | 45,392 | 18,788 | - | - | Stock Option (Right to Buy) | |
| PTC Therapeutics Inc | Mark E. Boulding | EXEC. VP AND CLO | Sale of securities on an exchange or to another person at price $ 53.15 per share. | 10 Mar 2025 | 45,392 | 103,901 (0%) | 0% | 53.2 | 2,412,585 | Common Stock |
| PTC Therapeutics Inc | Mark E. Boulding | EXEC. VP AND CLO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 33.02 per share. | 10 Mar 2025 | 45,392 | 149,293 (0%) | 0% | 33.0 | 1,498,844 | Common Stock |
| PTC Therapeutics Inc | Mark E. Boulding | EXEC. VP AND CLO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2025 | 11,398 | 4,114 | - | - | Stock Option (Right to Buy) | |
| PTC Therapeutics Inc | Mark E. Boulding | EXEC. VP AND CLO | Sale of securities on an exchange or to another person at price $ 53.12 per share. | 10 Mar 2025 | 11,398 | 103,901 (0%) | 0% | 53.1 | 605,462 | Common Stock |
| PTC Therapeutics Inc | Mark E. Boulding | EXEC. VP AND CLO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 33.02 per share. | 10 Mar 2025 | 11,398 | 115,299 (0%) | 0% | 33.0 | 376,362 | Common Stock |
| PTC Therapeutics Inc | Mark E. Boulding | EXEC. VP AND CLO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2025 | 11,249 | 33,751 | - | - | Stock Option (Right to Buy) | |
| PTC Therapeutics Inc | Mark E. Boulding | EXEC. VP AND CLO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 25.69 per share. | 10 Mar 2025 | 11,249 | 115,150 (0%) | 0% | 25.7 | 288,987 | Common Stock |
| PTC Therapeutics Inc | Mark E. Boulding | EXEC. VP AND CLO | Sale of securities on an exchange or to another person at price $ 53.05 per share. | 10 Mar 2025 | 7,762 | 103,901 (0%) | 0% | 53.0 | 411,774 | Common Stock |
| PTC Therapeutics Inc | Mark E. Boulding | EXEC. VP AND CLO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2025 | 5,662 | 13,126 | - | - | Stock Option (Right to Buy) | |
| PTC Therapeutics Inc | Mark E. Boulding | EXEC. VP AND CLO | Sale of securities on an exchange or to another person at price $ 53.02 per share. | 10 Mar 2025 | 5,662 | 103,901 (0%) | 0% | 53.0 | 300,199 | Common Stock |
| PTC Therapeutics Inc | Mark E. Boulding | EXEC. VP AND CLO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 33.02 per share. | 10 Mar 2025 | 5,662 | 109,563 (0%) | 0% | 33.0 | 186,959 | Common Stock |
| PTC Therapeutics Inc | Mark E. Boulding | EXEC. VP AND CLO | Sale of securities on an exchange or to another person at price $ 52.24 per share. | 10 Mar 2025 | 3,487 | 111,663 (0%) | 0% | 52.2 | 182,161 | Common Stock |
| PTC Therapeutics Inc | Mark E. Boulding | EXEC. VP AND CLO | Sale of securities on an exchange or to another person at price $ 53.01 per share. | 10 Mar 2025 | 1,719 | 103,901 (0%) | 0% | 53.0 | 91,124 | Common Stock |
| PTC Therapeutics Inc | Mark E. Boulding | EXEC. VP AND CLO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 33.02 per share. | 10 Mar 2025 | 1,719 | 105,620 (0%) | 0% | 33.0 | 56,761 | Common Stock |
| PTC Therapeutics Inc | Mark E. Boulding | EXEC. VP AND CLO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2025 | 1,719 | 2,395 | - | - | Stock Option (Right to Buy) | |
| PTC Therapeutics Inc | Mark E. Boulding | EXEC. VP AND CLO | Sale of securities on an exchange or to another person at price $ 50.12 per share. | 19 Feb 2025 | 1,614 | 103,901 (0%) | 0% | 50.1 | 80,900 | Common Stock |
| PTC Therapeutics Inc | Mark E. Boulding | EXEC. VP AND CLO | Sale of securities on an exchange or to another person at price $ 50.10 per share. | 19 Feb 2025 | 1,333 | 105,515 (0%) | 0% | 50.1 | 66,778 | Common Stock |
| PTC Therapeutics Inc | Mark E. Boulding | EXEC. VP AND CLO | Sale of securities on an exchange or to another person at price $ 44.50 per share. | 07 Jan 2025 | 1,998 | 106,848 (0%) | 0% | 44.5 | 88,911 | Common Stock |
| PTC Therapeutics Inc | Mark E. Boulding | EXEC. VP AND CLO | Sale of securities on an exchange or to another person at price $ 45.34 per share. | 07 Jan 2025 | 1,543 | 108,846 (0%) | 0% | 45.3 | 69,960 | Common Stock |
| PTC Therapeutics Inc | Mark E. Boulding | EXEC. VP AND CLO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2025 | 45,000 | 45,000 | - | - | Stock Option (Right to Buy) | |
| PTC Therapeutics Inc | Mark E. Boulding | EXEC. VP AND CLO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2025 | 18,000 | 110,389 (0%) | 0% | 0 | Common Stock | |
| PTC Therapeutics Inc | E. Mark Boulding | EXEC. VP AND CLO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 51.00 per share. | 02 Dec 2024 | 83,640 | 176,029 (0%) | 0% | 51 | 4,265,640 | Common Stock |
| PTC Therapeutics Inc | Boulding E. Mark | EXEC. VP AND CLO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Dec 2024 | 83,640 | 0 | - | - | Stock Option (Right to Buy) | |
| PTC Therapeutics Inc | Mark E. Boulding | EXEC. VP AND CLO | Sale of securities on an exchange or to another person at price $ 52.26 per share. | 02 Dec 2024 | 83,640 | 92,389 (0%) | 0% | 52.3 | 4,371,026 | Common Stock |
| PTC Therapeutics Inc | Boulding E. Mark | EXEC. VP AND CLO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 33.02 per share. | 02 Dec 2024 | 7,720 | 100,109 (0%) | 0% | 33.0 | 254,914 | Common Stock |
| PTC Therapeutics Inc | E. Boulding Mark | EXEC. VP AND CLO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Dec 2024 | 7,720 | 61,110 | - | - | Stock Option (Right to Buy) | |
| PTC Therapeutics Inc | Mark E. Boulding | EXEC. VP AND CLO | Sale of securities on an exchange or to another person at price $ 53.14 per share. | 02 Dec 2024 | 6,315 | 93,794 (0%) | 0% | 53.1 | 335,579 | Common Stock |
| PTC Therapeutics Inc | E. Mark Boulding | EXEC. VP AND CLO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 33.02 per share. | 02 Dec 2024 | 1,988 | 94,377 (0%) | 0% | 33.0 | 65,644 | Common Stock |
| PTC Therapeutics Inc | E. Mark Boulding | EXEC. VP AND CLO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Dec 2024 | 1,988 | 15,512 | - | - | Stock Option (Right to Buy) | |
| PTC Therapeutics Inc | E. Boulding Mark | EXEC. VP AND CLO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Dec 2024 | 1,960 | 83,640 | - | - | Stock Option (Right to Buy) | |
| PTC Therapeutics Inc | Boulding Mark E. | EXEC. VP AND CLO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 51.00 per share. | 02 Dec 2024 | 1,960 | 94,349 (0%) | 0% | 51 | 99,960 | Common Stock |
| PTC Therapeutics Inc | Mark E. Boulding | EXEC. VP AND CLO | Sale of securities on an exchange or to another person at price $ 52.17 per share. | 02 Dec 2024 | 1,960 | 92,389 (0%) | 0% | 52.2 | 102,253 | Common Stock |
| PTC Therapeutics Inc | Boulding Mark E. | EXEC. VP AND CLO | Sale of securities on an exchange or to another person at price $ 53.13 per share. | 02 Dec 2024 | 1,900 | 92,477 (0%) | 0% | 53.1 | 100,947 | Common Stock |
| PTC Therapeutics Inc | Mark Boulding E. | EXEC. VP AND CLO | Sale of securities on an exchange or to another person at price $ 54.05 per share. | 02 Dec 2024 | 1,405 | 92,389 (0%) | 0% | 54.0 | 75,940 | Common Stock |
| PTC Therapeutics Inc | Mark E. Boulding | EXEC. VP AND CLO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Dec 2024 | 600 | 3,070 | - | - | Stock Option (Right to Buy) | |
| PTC Therapeutics Inc | Mark Boulding E. | EXEC. VP AND CLO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 33.02 per share. | 02 Dec 2024 | 600 | 92,989 (0%) | 0% | 33.0 | 19,812 | Common Stock |
| PTC Therapeutics Inc | Mark Boulding E. | EXEC. VP AND CLO | Sale of securities on an exchange or to another person at price $ 53.04 per share. | 02 Dec 2024 | 600 | 92,389 (0%) | 0% | 53.0 | 31,824 | Common Stock |
| PTC Therapeutics Inc | Boulding E. Mark | EXEC. VP AND CLO | Sale of securities on an exchange or to another person at price $ 54.14 per share. | 02 Dec 2024 | 88 | 92,389 (0%) | 0% | 54.1 | 4,764 | Common Stock |
| PTC Therapeutics Inc | E. Boulding Mark | EXEC. VP AND CLO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Feb 2024 | 45,000 | 45,000 | - | - | Stock Option (Right to Buy) | |
| PTC Therapeutics Inc | E. Boulding Mark | EXEC. VP AND CLO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Feb 2024 | 18,000 | 89,189 (0%) | 0% | 0 | Common Stock | |
| PTC Therapeutics Inc | Mark Boulding E. | EXEC. VP AND CLO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Feb 2024 | 3,200 | 92,389 (0%) | 0% | 0 | Common Stock | |
| PTC Therapeutics Inc | Mark Boulding E. | EXEC. VP AND CLO | Sale of securities on an exchange or to another person at price $ 27.25 per share. | 30 Jan 2024 | 794 | 71,189 (0%) | 0% | 27.3 | 21,637 | Common Stock |
| PTC Therapeutics Inc | Mark E. Boulding | EXEC. VP AND CLO | Sale of securities on an exchange or to another person at price $ 29.01 per share. | 08 Jan 2024 | 1,938 | 71,983 (0%) | 0% | 29.0 | 56,231 | Common Stock |
| PTC Therapeutics Inc | Boulding Mark E. | EXEC. VP AND CLO | Sale of securities on an exchange or to another person at price $ 28.64 per share. | 08 Jan 2024 | 1,457 | 73,921 (0%) | 0% | 28.6 | 41,729 | Common Stock |
| PTC Therapeutics Inc | Mark E. Boulding | EXEC. VP AND CLO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Apr 2023 | 58,631 | 0 | - | - | Stock Option (Right to Buy) | |
| PTC Therapeutics Inc | Mark E. Boulding | EXEC. VP AND CLO | Sale of securities on an exchange or to another person at price $ 51.42 per share. | 17 Apr 2023 | 58,631 | 75,378 (0%) | 0% | 51.4 | 3,014,554 | Common Stock |
| PTC Therapeutics Inc | Mark E. Boulding | EXEC. VP AND CLO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 30.86 per share. | 17 Apr 2023 | 58,631 | 134,009 (0%) | 0% | 30.9 | 1,809,353 | Common Stock |
| PTC Therapeutics Inc | Mark E. Boulding | EXEC. VP AND CLO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Apr 2023 | 3,292 | 58,631 | - | - | Stock Option (Right to Buy) | |
| PTC Therapeutics Inc | Mark E. Boulding | EXEC. VP AND CLO | Sale of securities on an exchange or to another person at price $ 51.42 per share. | 17 Apr 2023 | 3,292 | 75,378 (0%) | 0% | 51.4 | 169,276 | Common Stock |
| PTC Therapeutics Inc | Mark E. Boulding | EXEC. VP AND CLO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 30.86 per share. | 17 Apr 2023 | 3,292 | 78,670 (0%) | 0% | 30.9 | 101,591 | Common Stock |
| PTC Therapeutics Inc | Mark E. Boulding | EXEC. VP AND CLO | Sale of securities on an exchange or to another person at price $ 45.63 per share. | 31 Jan 2023 | 812 | 75,378 (0%) | 0% | 45.6 | 37,050 | Common Stock |
| PTC Therapeutics Inc | Mark E. Boulding | EXEC. VP AND CLO | Sale of securities on an exchange or to another person at price $ 42.93 per share. | 10 Jan 2023 | 590 | 76,685 (0%) | 0% | 42.9 | 25,330 | Common Stock |
| PTC Therapeutics Inc | Mark E. Boulding | EXEC. VP AND CLO | Sale of securities on an exchange or to another person at price $ 44.36 per share. | 10 Jan 2023 | 495 | 76,190 (0%) | 0% | 44.4 | 21,958 | Common Stock |
| PTC Therapeutics Inc | Mark E. Boulding | EXEC. VP AND CLO | Sale of securities on an exchange or to another person at price $ 41.66 per share. | 09 Jan 2023 | 835 | 77,275 (0%) | 0% | 41.7 | 34,783 | Common Stock |
| PTC Therapeutics Inc | Mark E. Boulding | EXEC. VP AND CLO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jan 2023 | 36,250 | 36,250 | - | - | Stock Option (Right to Buy) | |
| PTC Therapeutics Inc | Mark E. Boulding | EXEC. VP AND CLO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jan 2023 | 17,000 | 78,110 (0%) | 0% | 0 | Common Stock | |
| PTC Therapeutics Inc | Mark E. Boulding | EXEC. VP AND CLO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Oct 2022 | 6,402 | 62,222 | - | - | Stock Option (Right to Buy) | |
| PTC Therapeutics Inc | Mark E. Boulding | EXEC. VP AND CLO | Sale of securities on an exchange or to another person at price $ 55.00 per share. | 17 Oct 2022 | 6,402 | 61,110 (0%) | 0% | 55 | 352,110 | Common Stock |
| PTC Therapeutics Inc | Mark E. Boulding | EXEC. VP AND CLO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 30.86 per share. | 17 Oct 2022 | 6,402 | 67,512 (0%) | 0% | 30.9 | 197,566 | Common Stock |
| PTC Therapeutics Inc | Mark E. Boulding | EXEC. VP AND CLO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Oct 2022 | 289 | 61,923 | - | - | Stock Option (Right to Buy) | |
| PTC Therapeutics Inc | Mark E. Boulding | EXEC. VP AND CLO | Sale of securities on an exchange or to another person at price $ 55.04 per share. | 17 Oct 2022 | 289 | 61,110 (0%) | 0% | 55.0 | 15,907 | Common Stock |
| PTC Therapeutics Inc | Mark E. Boulding | EXEC. VP AND CLO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 30.86 per share. | 17 Oct 2022 | 289 | 61,399 (0%) | 0% | 30.9 | 8,919 | Common Stock |
| PTC Therapeutics Inc | Mark E. Boulding | EXEC. VP AND CLO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 30.86 per share. | 17 Oct 2022 | 200 | 61,310 (0%) | 0% | 30.9 | 6,172 | Common Stock |
| PTC Therapeutics Inc | Mark E. Boulding | EXEC. VP AND CLO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Oct 2022 | 200 | 68,624 | - | - | Stock Option (Right to Buy) | |
| PTC Therapeutics Inc | Mark E. Boulding | EXEC. VP AND CLO | Sale of securities on an exchange or to another person at price $ 55.00 per share. | 17 Oct 2022 | 200 | 61,110 (0%) | 0% | 55 | 11,000 | Common Stock |
| PTC Therapeutics Inc | Mark E. Boulding | EXEC. VP AND CLO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Oct 2022 | 10 | 62,212 | - | - | Stock Option (Right to Buy) | |
| PTC Therapeutics Inc | Mark E. Boulding | EXEC. VP AND CLO | Sale of securities on an exchange or to another person at price $ 55.50 per share. | 17 Oct 2022 | 10 | 61,110 (0%) | 0% | 55.5 | 555 | Common Stock |
| PTC Therapeutics Inc | Mark E. Boulding | EXEC. VP AND CLO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 30.90 per share. | 17 Oct 2022 | 10 | 61,120 (0%) | 0% | 30.9 | 309 | Common Stock |
| PTC Therapeutics Inc | Mark E. Boulding | EXEC. VP AND CLO | Sale of securities on an exchange or to another person at price $ 55.00 per share. | 20 Sep 2022 | 876 | 61,110 (0%) | 0% | 55 | 48,180 | Common Stock |
| PTC Therapeutics Inc | Mark E. Boulding | EXEC. VP AND CLO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Sep 2022 | 876 | 69,124 | - | - | Stock Option (Right to Buy) | |
| PTC Therapeutics Inc | Mark E. Boulding | EXEC. VP AND CLO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 30.86 per share. | 20 Sep 2022 | 876 | 61,986 (0%) | 0% | 30.9 | 27,033 | Common Stock |
| PTC Therapeutics Inc | Mark E. Boulding | EXEC. VP AND CLO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Sep 2022 | 300 | 68,824 | - | - | Stock Option (Right to Buy) | |
| PTC Therapeutics Inc | Mark E. Boulding | EXEC. VP AND CLO | Sale of securities on an exchange or to another person at price $ 55.00 per share. | 20 Sep 2022 | 300 | 61,110 (0%) | 0% | 55 | 16,500 | Common Stock |
| PTC Therapeutics Inc | Mark E. Boulding | EXEC. VP AND CLO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 30.86 per share. | 20 Sep 2022 | 300 | 61,410 (0%) | 0% | 30.9 | 9,258 | Common Stock |
| PTC Therapeutics Inc | Mark E. Boulding | EXEC. VP AND CLO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Apr 2022 | 2,276 | 0 | - | - | Stock Option (Right to Buy) | |
| PTC Therapeutics Inc | Mark E. Boulding | EXEC. VP AND CLO | Sale of securities on an exchange or to another person at price $ 45.17 per share. | 13 Apr 2022 | 2,276 | 61,110 (0%) | 0% | 45.2 | 102,811 | Common Stock |
| PTC Therapeutics Inc | Mark E. Boulding | EXEC. VP AND CLO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 11.23 per share. | 13 Apr 2022 | 2,276 | 63,386 (0%) | 0% | 11.2 | 25,559 | Common Stock |
| PTC Therapeutics Inc | Mark E. Boulding | EXEC. VP AND CLO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 11.20 per share. | 05 Apr 2022 | 5 | 61,115 (0%) | 0% | 11.2 | 56 | Common Stock |
| PTC Therapeutics Inc | Mark E. Boulding | EXEC. VP AND CLO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Apr 2022 | 5 | 2,276 | - | - | Stock Option (Right to Buy) | |
| PTC Therapeutics Inc | Mark E. Boulding | EXEC. VP AND CLO | Sale of securities on an exchange or to another person at price $ 45.00 per share. | 05 Apr 2022 | 5 | 61,110 (0%) | 0% | 45 | 225 | Common Stock |
| PTC Therapeutics Inc | Mark E. Boulding | Exec. VP and CLO | Sale of securities on an exchange or to another person at price $ 40.00 per share. | 01 Feb 2022 | 779 | 61,110 (0%) | 0% | 40.0 | 31,162 | Common Stock |
| PTC Therapeutics Inc | Mark E. Boulding | Exec. VP and CLO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jan 2022 | 54,000 | 54,000 | - | - | Stock Option (Right to Buy) | |
| PTC Therapeutics Inc | Mark E. Boulding | Exec. VP and CLO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jan 2022 | 14,400 | 61,889 (0%) | 0% | 0 | Common Stock | |
| PTC Therapeutics Inc | Mark E. Boulding | Exec. VP and CLO | Sale of securities on an exchange or to another person at price $ 38.53 per share. | 07 Jan 2022 | 885 | 47,489 (0%) | 0% | 38.5 | 34,095 | Common Stock |
| PTC Therapeutics Inc | Mark E. Boulding | Exec. VP and CLO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Jul 2021 | 1,800 | 21,850 | - | - | Stock Option (Right to Buy) | |
| PTC Therapeutics Inc | Mark E. Boulding | Exec. VP and CLO | Sale of securities on an exchange or to another person at price $ 45.20 per share. | 08 Jul 2021 | 1,800 | 48,374 (0%) | 0% | 45.2 | 81,360 | Common Stock |
| PTC Therapeutics Inc | Mark E. Boulding | Exec. VP and CLO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 18.01 per share. | 08 Jul 2021 | 1,800 | 50,174 (0%) | 0% | 18.0 | 32,418 | Common Stock |
| PTC Therapeutics Inc | Mark E. Boulding | Exec. VP and CLO | Sale of securities on an exchange or to another person at price $ 45.22 per share. | 08 Jul 2021 | 1,500 | 48,374 (0%) | 0% | 45.2 | 67,832 | Common Stock |